Whilst curative for many, a large proportion (~40%) of patients undergoing RP will experience a biochemical recurrence (BCR) which is a rise in prostate specific antigen (PSA) levels in the blood indicating the recurrence of the tumour.3 Here, KLK3 is linked to neoplasm.